Clinical Trials

Clinical Trials

  Section Menu

CIMAvax Vaccine

Roswell Park has launched the first clinical trial in the U.S. to study the CIMAvax-EGF ® vaccine, a lung cancer treatment. Learn more about CIMAvax.

A clinical trial is a study designed to evaluate a promising new medical treatment. It includes research done to evaluate new ways to prevent and diagnose and/or treat cancer. At Roswell Park, up to 50% of our patients are eligible to enter clinical trials. Many types of treatment can be tested including:

  • New ways of preventing cancer such as drugs, diet, and/or exercise
  • New drugs to treat cancer
  • New ways to use existing treatment such as surgery or radiation therapy

When clinical trials identify new and effective treatments, these treatments will eventually become the new standard of care that will be offered to future patients. Today’s standard treatments were researched and proven by clinical trials done in the past.

Should I participate in a clinical trial? (Learn more about clinical trials from the NCI.)

Recently Opened Clinical Trials

(NRG-GI004/SWOG-S1610) Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevaczumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment...
Principal Investigator:
Boland, Patrick M
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
Principal Investigator:
Chatta, Gurkamal S
Phase II Study of Targeting CD28 in Multiple Myeloma with Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy
Principal Investigator:
Lee, Kelvin
(H125001) An Open-Label Phase 1 / 2 Study of JCARH125, BCMA targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed and/or Refractory Multiple Myeloma
Principal Investigator:
Lee, Kelvin
(IRB17-0578) Phase I study of stereotactic body radiotherapy (SBRT) followed by nivolumab or ipilimumab with nivolumab in unresectable hepatocellular carcinoma
Principal Investigator:
Iyer, Renuka V
(ADP-0000-001) A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or...
Principal Investigator:
Odunsi, Adekunle O
A DOSE-FINDING PHASE 1 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS WITH OR WITHOUT FIBROBLAST GROWTH FACTOR/RECEPTOR (FGF/FGFR)-RELATED ABNORMALITIES FOLLOWED BY A PHASE 2 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS WITH FGF/FGFR-RELATED...
Principal Investigator:
Iyer, Renuka V